In Brief: Vitacost Bends To Investors, Actavis Makes Asian Moves, DSM Courts Vitamin C Firm
This article was originally published in The Tan Sheet
Executive Summary
Truce for Vitacost, investors; Actavis buys Silom Medical; DSM courts Aland; ChromaDex shares product libraries; Tenn. blocks drug felons buying PSE; FTC finalizes L’Occitane settlement; and more In Brief.
You may also be interested in...
Vitacost Weighs Options After Losses; Shareholder Airs Complaints
Activist shareholder Consac urges Vitacost.com to sell after operating losses four years in a row, despite close to $400 million in annual sales.
FTC Settles Big With Sensa, Other Weight-Loss Marketers
FTC settles with Sensa products and three other weight-loss product marketers, and launches its “gut check” voluntary media partnership program to prevent bogus claims. A firm cited in FTC’s 2011 investigation of human chorionic gonadotropin product ads also reached a settlement with the agency.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”